 Market.JPG)
Living Therapeutic Agents (LTA) Market Size is valued at US$ 116.5 Bn in 2024 and is predicted to reach US$ 364.8 Bn by the year 2034 at an 12.5% CAGR during the forecast period for 2025-2034.
-Market-Info.webp "Living Therapeutic Agents (LTA) Market info")
Living therapeutic agents (LTAs) are used to stop, help, and take care of many sicknesses, like cancer, problems with the body's defense system, issues with how the body uses food, and brain problems. These helpers, such as changed bacteria, viruses, and cells, give treatments that go right to the problem, change how the body fights sickness, get the body's natural germs back in order, and help body parts grow back.
LTAs are used in special medicine to make treatments work better and have fewer bad effects, which means treatments can be made just for each person. They are also used to give gene therapy, use the body's germs to help, and make the newest types of biological medicines. By using living things, LTAs offer new, flexible, and very focused ways to help people feel better in many clinics and studies.
The global market for living therapeutic agents (LTA) is expanding due to the rise in chronic and genetic disease prevalence, rise in demand for personalised medicine, advancements in biotechnologies, and growing investments on microbiome-based and next-generation biologicals. Furthermore, increasing chronic and genetic diseases is an other factor pushing the living therapeutic agents (LTA) market. Growth in the prevalence of chronic and genetic disorders boost the need for living therapeutic agents which is promising personalized, better, and safer therapeutics as compared to traditional drugs.
However, high R&D and manufacturing cost, complex approval by regulatory authorities and safety issues are some of the barriers which hinder the growth of living therapeutic agents (LTA) market. Opportunities in the living therapeutic agents (LTA) market includes growing application of precision medicine including microbiome-mediated therapies and gene targeted interventions.
Some of the Key Players in Living Therapeutic Agents (LTA) Market:
· Seres Therapeutics
· Synlogic
· Finch Therapeutics
· Evelo Biosciences
· Vedanta Biosciences
· Rebiotix
· Enterome
· BiomX
· Novome Biotechnologies
· Second Genome
· Ferring Pharmaceuticals
· Takeda Pharmaceutical
· Johnson & Johnson
· Merck KGaA
· Eligo Bioscience
· OxThera
· Axial Biotherapeutics
· CSL Behring
· Ginkgo Bioworks
· BlueRock Therapeutics
· Oragenics
The living therapeutic agents (LTA) market is segmented by type, application, route of administration, and end-user. by type, the market is segmented into live biotherapeutic products, cell-based therapies, and genetically engineered microbes. By application, the market is segmented into gastrointestinal disorders, infectious diseases, oncology, metabolic disorders, and immune-related conditions. By route of administration, the market is segmented into oral therapeutics, injectable, topical. By end user, the market is segmented into hospitals, research institutes, and specialty clinics.
The live biotherapeutic products category led the living therapeutic agents (LTA) market in 2024. This convergence is because of their proven clinical efficacy and well-established regulatory procedures. Due to their approval for recurrent infections like C. difficile, they are widely used and cost a lot of money. Demand is further increased by their ability to provide targeted microbial therapy and their simplicity of administration, either orally or rectally. Biotherapeutics stands out from other LTA types thanks to a robust manufacturing infrastructure, clear FDA guidance, and an expanding trial pipeline, which draws in developers and healthcare providers alike and maintains their market leadership.
The largest and fastest-growing application is gastrointestinal disorders, a trend is due to widespread occurrence of ailments such inflammatory bowel disease, recurrent C. difficile infections, and irritable bowel syndrome has prompted the use of LBPs as efficient substitutes for traditional treatments. Specific live biotherapeutic strains have been shown in clinical trials and empirical data to enhance patient outcomes, lower inflammation, and restore the balance of the gut microbiota.
The market for infectious diseases is expanding significantly as well, especially when considering hospital-acquired infections and drug resistance. In order to combat multidrug-resistant infections, LBPs are being developed as either alone or as adjunct therapy, providing patients with few treatment options with new hope.
North America dominated the living therapeutic agents (LTA) market in 2024. The United States is at the forefront of this expansion. This is due to robust biopharmaceutical ecosystem, a willingness to embrace new therapies, and substantial research and development investments. There is an abundance of telehealth. There are major biotech companies, well-established clinical trial networks, and favorable regulatory environments that allow for faster development and commercialization of biomedical technologies. Demand is also driven by the increasing prevalence of chronic and genetic diseases, high health care spending, and patient awareness, enabling North America to have the largest global market share.
Asia Pacific region is expanding at the strongest and fastest rate due to increasing investments from the government, growing acceptance of new therapies and rising prevalence of chronic and genetic disorders Additionally, The growing awareness of patients, the growing healthcare infrastructure, and the growing population density are driving the rise in demand for the utilization of personalized targeted living therapeutic agents, leading to rapid expansion regionally.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 116.5 Bn |
|
Revenue Forecast In 2034 |
USD 364.8 Bn |
|
Growth Rate CAGR |
CAGR of 12.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Application, By Route of Administration, By End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
|
Competitive Landscape |
Seres Therapeutics, Synlogic, Finch Therapeutics, Evelo Biosciences, Vedanta Biosciences, Rebiotix, Enterome, BiomX, Novome Biotechnologies, Second Genome, Ferring Pharmaceuticals, Takeda Pharmaceutical, Johnson & Johnson, Merck KGaA, and Eligo Bioscience, OxThera, Axial Biotherapeutics, CSL Behring, Ginkgo Bioworks, BlueRock Therapeutics, Oragenics. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Living Therapeutic Agents (LTA) Market Snapshot
Chapter 4. Global Living Therapeutic Agents (LTA) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on Living Therapeutic Agents (LTA) Market Industry Trends
4.10. Global Living Therapeutic Agents (LTA) Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
Chapter 5. Living Therapeutic Agents (LTA) Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Live Biotherapeutic Products
5.2.2. Cell-based Therapies
5.2.3. Genetically Engineered Microbes
Chapter 6. Living Therapeutic Agents (LTA) Market Segmentation 2: Route of Administration, Estimates & Trend Analysis
6.1. Market Share by Route of Administration, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
6.2.1. Oral Therapeutics
6.2.2. Injectable
6.2.3. Topical
Chapter 7. Living Therapeutic Agents (LTA) Market Segmentation 3: By Application, Estimates &
Trend Analysis
7.1. Market Share by Application, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Gastrointestinal Disorders
7.2.2. Infectious Diseases
7.2.3. Oncology
7.2.4. Metabolic Disorders
7.2.5. Immune-related Conditions
Chapter 8. Living Therapeutic Agents (LTA) Market Segmentation 4: By End User, Estimates & Trend Analysis
8.1. Market Share by End User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
8.2.1. Hospitals
8.2.2. Research Institutes
8.2.3. Specialty Clinics
Chapter 9. Living Therapeutic Agents (LTA) Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Living Therapeutic Agents (LTA) Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.2.3. North America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.4. North America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.5. North America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3. Europe
9.3.1. Europe Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.3.3. Europe Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.4. Europe Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.5. Europe Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.4.3. Asia Pacific Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.4. Asia Pacific Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.5. Asia Pacific Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5. Latin America
9.5.1. Latin America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.5.3. Latin America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.4. Latin America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.5. Latin America Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.6.3. Middle East & Africa Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.6.4. Middle East & Africa Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.5. Middle East & Africa Living Therapeutic Agents (LTA) Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. 4D Pharma (UK)
10.2.1.1. Business Overview
10.2.1.2. Key Product /Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Seres Therapeutics (USA)
10.2.3. Synlogic (USA)
10.2.4. Finch Therapeutics (USA)
10.2.5. Evelo Biosciences (USA)
10.2.6. Vedanta Biosciences (USA)
10.2.7. Rebiotix (USA)
10.2.8. Enterome (France)
10.2.9. BiomX (Israel)
10.2.10. Novome Biotechnologies (USA)
10.2.11. Second Genome (USA)
10.2.12. Ferring Pharmaceuticals (Switzerland)
10.2.13. Takeda Pharmaceutical (Japan)
10.2.14. Johnson & Johnson (USA)
10.2.15. Merck KGaA (Germany)
10.2.16. Eligo Bioscience (France)
10.2.17. OxThera (Sweden)
10.2.18. Axial Biotherapeutics (USA)
10.2.19. CSL Behring (Australia)
10.2.20. Ginkgo Bioworks (USA)
10.2.21. BlueRock Therapeutics (USA)
10.2.22. Oragenics (USA)
Living Therapeutic Agents (LTA) Market by Type
· Live Biotherapeutic Products
· Cell-based Therapies
· Genetically Engineered Microbes
-Market-Seg.webp "Living Therapeutic Agents (LTA) Market seg")
Living Therapeutic Agents (LTA) Market by Application
· Gastrointestinal Disorders
· Infectious Diseases
· Oncology
· Metabolic Disorders
· Immune-related Conditions
Living Therapeutic Agents (LTA) Market by Route of Administration
· Oral Therapeutics
· Injectable
· Topical
Living Therapeutic Agents (LTA) Market by End User
· Hospitals
· Research Institutes
· Specialty Clinics
Living Therapeutic Agents (LTA) Market by Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
